PSCR (Proto Script Pharmaceutical) Debt-to-EBITDA : -0.57 (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Proto Script Pharmaceutical Debt-to-EBITDA?

Proto Script Pharmaceutical PSCR Debt-to-EBITDA is -0.57 as of Sep. 2017.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Proto Script Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.37 Mil. Proto Script Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Proto Script Pharmaceutical's annualized EBITDA for the quarter that ended in Sep. 2017 was $-0.66 Mil. Proto Script Pharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2017 was -0.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Proto Script Pharmaceutical's Debt-to-EBITDA or its related term are showing as below:

PSCR's Debt-to-EBITDA is not ranked *
in the Business Services industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Proto Script Pharmaceutical  (OTCPK:PSCR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Proto Script Pharmaceutical Debt-to-EBITDA Related Terms

Proto Script Pharmaceutical Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Proto Script Pharmaceutical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proto Script Pharmaceutical Debt-to-EBITDA Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Debt-to-EBITDA
0.00 0.00 0.00 0.00 0.00

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.50 -0.03 -0.19 -0.28 -0.57

PSCR vs EXCC, NXES, PRZM: Debt-to-EBITDA Comparison

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proto Script Pharmaceutical Debt-to-EBITDA vs Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's Debt-to-EBITDA falls into.


Proto Script Pharmaceutical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Proto Script Pharmaceutical's Debt-to-EBITDA for the fiscal year that ended in May. 2016 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.033
=0.00

Proto Script Pharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.373 + 0) / -0.656
=-0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2017) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.57 mean?
Proto Script Pharmaceutical (PSCR) has a Debt-to-EBITDA of -0.57 as of Sep. 2017. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Proto Script Pharmaceutical.
Is Proto Script Pharmaceutical's Debt-to-EBITDA too high?
Proto Script Pharmaceutical's current Debt-to-EBITDA is -0.57.
How does Proto Script Pharmaceutical's Debt-to-EBITDA compare to EXCC and NXES?
Proto Script Pharmaceutical's Debt-to-EBITDA of -0.57 can be compared against companies in the Business Services industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Business Services company?
The median Debt-to-EBITDA among Business Services companies is 1.67, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Proto Script Pharmaceutical. For the Business Services industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proto Script Pharmaceutical's current Debt-to-EBITDA is -0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proto Script Pharmaceutical stock overvalued right now?
Proto Script Pharmaceutical (PSCR) has a current Debt-to-EBITDA of -0.57. The current Debt-to-EBITDA is -0.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Proto Script Pharmaceutical (PSCR), the current Debt-to-EBITDA is -0.57 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proto Script Pharmaceutical Business Description

Address 9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.